These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16413688)

  • 1. Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases?
    Delibasi T; Akkus NI; Altundag O; Pinar T; Altundag K
    Med Hypotheses; 2006; 66(6):1254-5. PubMed ID: 16413688
    [No Abstract]   [Full Text] [Related]  

  • 2. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monthly tablet in postmenopausal osteoporosis].
    Krankenpfl J; 2005; 43(7-10):216. PubMed ID: 16515288
    [No Abstract]   [Full Text] [Related]  

  • 8. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
    Middleton ET; Steel SA; Doherty SM
    Calcif Tissue Int; 2007 Nov; 81(5):335-40. PubMed ID: 17938845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonates: a once-yearly treatment option with Reclast.
    Van Gilder D
    S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136
    [No Abstract]   [Full Text] [Related]  

  • 12. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ibandronate (Boniva).
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):68-9. PubMed ID: 16977282
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M
    Breast; 2006 Feb; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
    Bedard PL; Body JJ; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Sep; 27(25):4043-6. PubMed ID: 19652062
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
    Sakurai T
    Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.